http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012136113-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-10001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-179 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2011-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012136113-A |
| titleOfInvention | AXL SIGNAL INHIBITION IN ANTIMETASTATIC THERAPY |
| abstract | 1. A soluble variant of the AXL polypeptide, where the polypeptide does not have an AXL transmembrane domain and includes at least one amino acid modification compared to the wild-type AXL sequence, and in which the claimed change increases the binding affinity of the AXL polypeptide with GAS6.2. The soluble variant of the AXL polypeptide according to claim 1, characterized in that the soluble variant of the AXL polypeptide contains at least one amino acid modification in a section selected from the group consisting of 1) between 15-50, 2) between 60-120 and 3 ) between 125-135 wild-type AXL sequences (SEQ ID NO: 1) .3. The soluble variant of the AXL polypeptide according to claim 1, characterized in that the soluble variant of the AXL polypeptide contains at least one amino acid modification at position 19, 23, 26, 27, 32, 33, 38, 44, 61, 65, 72, 74, 78, 79, 86, 87, 88, 90, 92, 97, 98, 105, 109, 112, 113, 116, 118 or 127 wild-type AXL sequences (SEQ ID NO: 1), or a combination thereof. . The soluble variant of the AXL polypeptide according to claim 1, characterized in that the soluble variant of the AXL polypeptide contains at least one amino acid modification selected from the group consisting of 1) A19T, 2) T23M, 3) E26G, 4) E27G or E27K, 5) G32S, 6) N33S, 7) T38I, 8) T44A, 9) H61Y, 10) D65N, 11) A72V, 12) S74N, 13) Q78E, 14) V79M, 15) Q86R, 16) D87G, 17) D88N, 18) I90M or I90V, 19) V92A, V92G or V92D, 20) I97R, 21) T98A or T98P, 22) T105M, 23) Q109R, 24) V112A, 25) F113L, 26) H116R, 27) T118A, 28) G127R or G127E and 29) G129E, and combinations thereof. 5. The soluble variant of the AXL polypeptide according to claim 1, characterized in that the variant AXL includes amino acid substitution in comparison with the wild-type AXL sequence (SEQ ID NO: 1) at the following positions: (a) glycine 32; (b) aspartic acid 87; (c) valine 92; and (d) glycine 127.6. A soluble variant of the AXL polypeptide according to claim 1, characterized in that the glycine residue 32 is replaced by a residue |
| priorityDate | 2010-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.